News

Azithromycin treatment initiated during hospitalization for an acute exacerbation of chronic obstructive pulmonary disease (COPD), followed by three months of a low-maintenance dose, seems to reduce treatment failure. The results were reported in “Azithromycin during Acute COPD Exacerbations Requiring Hospitalization (BACE): a Multicentre, Randomized, Double-blind, Placebo-controlled Trial,” published in…

Video telehealth rehabilitation reduced the rates that patients with chronic obstructive pulmonary disease (COPD) had to be readmitted within 30 days after they were hospitalized for a pulmonary exacerbation, according to a study. The findings were published in the American Journal of Respiratory and Critical Care Medicine in a…

With the prevalence of type 2 diabetes and chronic obstructive pulmonary disease (COPD) rising, a team of researchers is discussing the latest research linking both diseases, and the recommended therapeutic approaches for patients with coexisting COPD and diabetes. The study “COPD and Type 2 Diabetes,” published in the journal…

Chronic obstructive pulmonary disease (COPD) patients who are exposed frequently to biomass smoke emitted by burning wood and coal have a similar risk of exacerbation — acute pulmonary symptoms worsening — as patients who smoke tobacco, a study suggests. As a result of this finding, biomass smoke should be…

Canadian wellness app Carrot Rewards has announced a new campaign in collaboration with The Lung Association — Ontario and Boehringer Ingelheim (Canada) to reach chronic obstructive pulmonary disease (COPD) patients and educate users about the disease. Carrot Rewards is an artificial intelligence-driven wellness app and brand engagement…

The Loop wristband device, designed to remotely monitor the condition of patients with chronic diseases such as chronic obstructive pulmonary disease (COPD), received marketing clearance from the U.S. Food and Drug Administration (FDA), announced the device’s developer, Spry Health. Loop is a wearable technology that measures pulse…

CSA Medical‘s RejuvenAir System received the designation of Breakthrough Device by the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic obstructive pulmonary disease (COPD). The FDA also gave the company an unconditional Investigational Device Exemption (IDE) approval to test the system in…

Myth 1: If you can’t run with the big dogs, stay on the porch.  Truth: In the words of the late great Dr. Martin Luther King Jr., “if you can’t fly then run, if you can’t run then walk, if you can’t walk then crawl, but whatever you do you…

The U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application for the addition of new clinical data on on the label of Tudorza (aclidinium bromide), a bronchodilator for the long-term treatment of chronic obstructive pulmonary disease (COPD) marketed by Circassia Pharmaceuticals…

Circassia announced that the U.S. Food and Drug Administration (FDA) approved its medication Duaklir for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The company plans to launch the therapy in the United States in the second half of 2019. Duaklir is a combination of two…